HKHiroaki Kanzaki

Hiroaki Kanzaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroaki Kanzaki has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal changes in a blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in cirrhosis

    by Hiroyuki Suzuki, Camden Lopez, Courtney Katz, Hiroaki Kanzaki, Naoto Fujiwara, Ece Janet Dinc, Stephanie Page-Lester, Pratibha Selvakumar, Indu Raman, Prithvi Raj, et al.

    Background and Aims: Hepatocellular carcinoma (HCC) risk in patients with cirrhosis can be predicted by cross-sectional assessment of biomarkers and/or clinical scores, including the Prognostic Liver Secretome signature (PLSec)-based PAaM score. However, HCC risk may change over time, potentially limiting the accuracy of cross-sectional risk prediction. We aimed to evaluate whether longitudinal changes in HCC risk biomarkers/scores improve upon one-time risk assessment. Approach and Results: In this nested case-control study within the multi-center prospective National Cancer Institute HCC Early Detection Strategy (HEDS) cohort of patients with cirrhosis, we evaluated longitudinal changes in PLSec over 1 or 2 years. Paired baseline and follow-up serum samples were available for 31 cases and 93 controls for 1-year changes, and for 25 cases and 75 controls for 2-year changes. Cross-sectional PLSec scores were higher in cases than in controls at baseline, Year 1, and Year 2 ( p p =0.026; AUROC, 0.65; adjusted odds ratio, 1.47 [95% CI, 1.04–2.15]). In multivariable logistic regression, delta-PLSec-Y2 remained significantly associated with HCC risk ( p =0.041) along with baseline PAaM. Conclusions: Longitudinal assessment of PLSec at a 2-year interval may provide additional information to refine cross-sectional HCC risk assessment, warranting further independent validation, evaluation of longer intervals, and exploration of optimal re-testing frequency.

  • Open Access

    Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma

    by Masanori Inoue, Sadahisa Ogasawara, Kazuhisa Asahara, Rui Sato, Shunji Watanabe, Haruka Anzai, Kazuo Tsubura, Taro Watabe, Makoto Fujiya, Teppei Akatsuka, et al.

    Introduction: Atezolizumab plus bevacizumab (Atez/Bev) has become the standard first‐line therapy for advanced hepatocellular carcinoma (HCC), but optimal second‐line strategies remain unclear. This multicenter retrospective study compared survival outcomes and tumor control among first‐line regimens and evaluated post‐progression efficacy. Methods: We retrospectively analyzed 1542 patients with advanced HCC who received sorafenib (SOR), lenvatinib (LEN), or Atez/Bev between 2009 and 2022. The main cohort ( n = 612) excluded patients who underwent concomitant or inter‐line locoregional therapy or entered clinical trials after first‐line treatment. Overall survival (OS), progression‐free survival (PFS), post‐progression survival (PPS), duration of disease control (DDC), and duration of response (DOR) were estimated by Kaplan–Meier analysis and compared by the log‐rank test. The impact of disease control and objective response on OS was assessed using time‐dependent Cox models. Results: Median OS was 15.4 months for SOR, 13.1 for LEN, and 20.6 for Atez/Bev ( p = 0.002); Median PFS was 3.5, 5.7, and 7.5 months, respectively ( p < 0.001); and median PPS was 10.8, 6.4, and 9.0 months, respectively ( p = 0.049). Atez/Bev achieved the longest DDC (8.5 months) and DOR (22.1 months). Disease control and objective response were associated with improved OS (HR: 0.51/0.42 for SOR, 0.54/0.62 for LEN, 0.34/0.35 for Atez/Bev). After progression, median second‐line PFS was 5.5 months for SOR, 2.5 for LEN, and 3.0 for Atez/Bev ( p = 0.001). Conclusion: Atez/Bev provided superior survival and durable tumor control; however, post‐progression outcomes remained unsatisfactory, underscoring the need for improved second‐line approaches after Atez/Bev failure.


  • The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance

    by Rocio I.R. Macias, Hiroaki Kanzaki, Carmen Berasain, Matias A. Avila, Jose J.G. Marin, Yujin Hoshida


  • A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study

    by Kazufumi Kobayashi, Sadahisa Ogasawara, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yuki Haga, Yuya Seko, Michihisa Moriguchi, Shunji Watanabe, Yuki Shiko, et al.

    Purpose: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from the REFLECT trial, a phase III trial that compared lenvatinib with sorafenib. Patients and Methods: This multicenter, nonrandomized, open-label prospective study was conducted at 10 medical facilities in Japan (jRCTs031190017). Eligible patients had advanced hepatocellular carcinoma (HCC) and were suitable for lenvatinib therapy. The study included patients with high tumor burden (with >50% intrahepatic tumor volume, main portal vein invasion, or bile duct invasion), Child-Pugh B status, and receiving lenvatinib as second-line therapy following atezolizumab plus bevacizumab. Results: From December 2019 to September 2021, 59 patients were analyzed (47 and 12 patients with Child-Pugh A and B, respectively). In patients with Child-Pugh A, the frequency of aspartate aminotransferase elevation was high (72.7%) in the high-burden group. No other significant ad verse events (AE) were observed even in second-line treatment. However, patients with Child-Pugh B had high incidence of grade ≥3 AE (100.0%) and high discontinuation rates caused by AE (33.3%) compared with patients with Child-Pugh A (80.9% and 17.0%, respectively). Median progression-free survival was 6.4 and 2.5 months and median overall survival was 19.7 and 4.1 months in Child-Pugh A and B, respectively. Lenvatinib plasma concentration was higher in patients with Child-Pugh B on days 8 and 15 and correlated with dose modifications and lower relative dose intensity. Conclusions: Lenvatinib is safe and effective for advanced HCC in patients with Child-Pugh A, even with high tumor burden. However, it carries a higher risk of AE and may not provide adequate efficacy for patients with Child-Pugh B status.